SciCombinator

Discover the most talked about and latest scientific content & concepts.

Abstract
Early randomized controlled trials (RCTs) demonstrated the health benefits of omega-3 fatty acids (n-3), whereas recent RCTs were negative. We now address the issue, focusing on the temporal changes having occurred: most patients in recent RCTs are no longer n-3 deficient and the vast majority are now treated with statins. Recent RCTs testing n-3 against arrhythmias suggest that n-3 reduce the risk only in patients not taking a statin. Other recent RCTs in secondary prevention were negative although, in a post-hoc analysis separating statin users and non-users, non-significant protection of n-3 was observed among statin non-users whereas statin users had no effect. Recent RCTs testing statins - after the implementation of the New Clinical Trial Regulation in 2007 - are negative (or flawed) suggesting that the lack of effect of n-3 cannot be attributed to a parallel protection by statins. Finally, statins favor the metabolism of omega-6 fatty acids (n-6), which in turn inhibits n-3 and, contrary to n-3, they increase insulin resistance and the risk of diabetes.Thus, n-3 and statins are counteractive at several levels and statins appear to inhibit n-3.
Tweets*
48
Facebook likes*
14
Reddit*
0
News coverage*
0
Blogs*
0
SC clicks
2
Concepts
Omega-9 fatty acid, Nutrition, Clinical research, Triglyceride, Essential fatty acid, Omega-6 fatty acid, Fatty acid, Omega-3 fatty acid
MeSH headings
-
comments powered by Disqus

* Data courtesy of Altmetric.com